Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
| العنوان: | Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin |
|---|---|
| المؤلفون: | Rami Moucari, N. Giuily, Tarik Asselah, Michelle Martinot-Peignoux, Marie-Pierre Ripault, Anne Auperin, Patrick Marcellin, Corinne Castelnau, Michèle Pouteau, Christiane Stern, Pierre Bedossa, Ana-Carolina Cardoso, Nathalie Boyer, Sarah Maylin |
| المصدر: | Antiviral Therapy. 14:501-511 |
| بيانات النشر: | SAGE Publications, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Time Factors, Interferon alpha-2, Antiviral Agents, Gastroenterology, Polyethylene Glycols, Virological response, chemistry.chemical_compound, Predictive Value of Tests, Pegylated interferon, Interferon, Internal medicine, Ribavirin, Humans, Medicine, Pharmacology (medical), Pharmacology, business.industry, Interferon-alpha, Hepatitis C, Middle Aged, medicine.disease, Predictive value, Recombinant Proteins, Predictive factor, Treatment Outcome, Infectious Diseases, chemistry, Immunology, RNA, Viral, Drug Therapy, Combination, Female, Viral disease, business, medicine.drug |
| الوصف: | Background Viral kinetics during therapy provides information on how to individualize treatment. To determine the benefit of assessing positive predictive values (PPVs) and negative predictive values (NPVs) of rapid virological responses (RVRs) and early virological responses (EVRs), on-treatment outcomes in chronic hepatitis C patients were examined. Methods A total of 408 patients (221 treatment-naive) treated with pegylated interferon-α2b and ribavirin were included. Hepatitis C virus (HCV) RNA was measured at baseline, 4 weeks and 12 weeks. RVR was defined as undetectable HCV RNA at 4 weeks and EVR as ≥2 log10 decrease in HCV RNA at 12 weeks. The additive value of RVR on predicting sustained virological response (SVR) was assessed with receiver operating characteristic (ROC) curves. Results SVR, RVR and EVR were observed in 46%, 23% and 78% of patients, respectively. PPVs of RVR were 96%, 100% and 100% in treatment-naive patients, relapsers and non-responders, respectively. NPVs of failure to achieve EVR were 97%, 75% and 91%, in treatment- naive patients, relapsers and non-responders, respectively. At 4 weeks, patients with RVR had the highest probability to achieve SVR (odds ratio 44.98 in the entire population and 32.95 in treatment-naive patients). ROC curves showed the area under the ROC curve to be 0.758 versus 0.832 in the entire population and 0.795 versus 0.858 in treatment-naive patients at baseline versus week 4, respectively. Conclusions RVR is a strong predictor of SVR (PPV>96%) and failure to achieve EVR is a strong predictor of non-SVR (NPV>75%), independent of patients’ pretreatment status. Added to baseline characteristics, RVR increased the accuracy to predict SVR. The combination of RVR and EVR provided complementary information, and thus provides a key opportunity to individualize treatment and improve the benefit/risk ratio of therapy. |
| تدمد: | 2040-2058 1359-6535 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e55c680679a7fc0a532174cf06e0b20Test https://doi.org/10.1177/135965350901400403Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....5e55c680679a7fc0a532174cf06e0b20 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20402058 13596535 |
|---|